{"contentid": 488293, "importid": NaN, "name": "Roadblock for Ryvu's novel kinase blocker", "introduction": "In the USA, a partial clinical hold has been placed on a Phase Ib trial of RVU120, being undertaken by Krakow-based Ryvu Therapeutics.", "content": "<p>In the USA, a partial clinical hold has been placed on a Phase Ib trial of RVU120, being undertaken by Krakow-based Ryvu Therapeutics (WSE: RVU).</p>\n<p>Shares in the Polish oncology specialist fell over 10% after the opening bell on Friday.</p>\n<p>Ryvu, which is focused on developing novel small molecules, believes the selective CDK8/CDK19 kinase inhibitor has potential for the treatment of blood cancer and solid tumors.</p>\n<p>The US Food and Drug Administration stopped the trial of Ryvu&rsquo;s lead candidate after the firm reported a patient death, which it said &ldquo;may possibly be related to RVU120.&rdquo;</p>\n<p>The trial program is designed to investigate RVU120, which is also known as SEL120, in people with relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).</p>\n<p>The company said it plans to work diligently with the agency to address the comments and request, in order to resolve the partial clinical hold.</p>\n<h2>Ryvu progress</h2>\n<p>Founded in 2019, Ryvu was formed when the oncology therapeutics and contract research business units at Polish company Selvita (WSE: SLV) were split.</p>\n<p>The new biotech subsequently inked a research collaboration with Belgium&rsquo;s Galapagos (Euronext: GLPG), aimed at the discovery and development of small-molecule drugs in inflammation.</p>\n<p>In addition to its lead candidate, Ryvu is developing MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group and currently in Phase II studies in AML.</p>\n<p>Commenting on the partial clinical hold, chief executive Pawel Przewiezlikowski said: \"Based on the totality of the data we have for RVU120, we believe that it continues to be a promising treatment option for cancer patients, and we will continue to work closely with the FDA to resolve the partial clinical hold with the objective of resuming enrollment in the study.&rdquo;</p>\n<p>&ldquo;We remain on track to present detailed interim safety and efficacy data at upcoming scientific conferences,&rdquo; he added.</p>", "date": "2021-04-09 10:25:00", "meta_title": NaN, "meta_keywords": "Ryvu, partial, clinical, hold, trial, kinase, therapeutics, Phase, Roadblock, blocker, undertaken, Krakow-based, Polish, oncology, focused, developing, bel", "meta_description": "In the USA, a partial clinical hold has been placed on a Phase Ib trial of RVU120, being undertaken by Krakow-based Ryvu Therapeutics.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-09 09:59:10", "updated": "2021-04-09 10:26:37", "access": NaN, "url": "https://www.thepharmaletter.com/article/roadblock-for-ryvu-s-novel-kinase-blocker", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "ryvu_large.png", "image2id": "ryvu_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Oncology", "topic_tag": "Drug Trial, Focus On, Regulation, Research, US FDA", "geography_tag": "Poland, USA", "company_tag": "Ryvu Therapeutics", "drug_tag": "RVU120", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-09 10:25:00"}